Hereditary degenerations of the retina (IRDs) are a group of genetic disorders that lead to progressive vision loss as cells that detect eye light-DIE due to mutations in genes required for their function and survival.
Genetic therapy has been highlighted as a very promising approach, replacement or supplementation of defective genes to maintain or restore vision. However, most existing gene therapy strategies have been developed and tested in the early stages of the disease, resulting in a significant gap in the treatment of patients diagnosed after significant retinal damage.
Now, in a study published in Molecular therapyResearchers from the Department of Experimental Therapies of the retina at the Veterinary School of the University of Pennsylvania (Penn Vet) and their partners have developed a strong new tool to help close this gap.
Led by Raghavi Sudharsan of Penn Vet, Assistant Professor of Experimental Ophthalmology and William A. Beltran, Corinne R. Henry Bower, who emerged as a professor of ophthalmology, developed four new special photocopies promoters. These “small parts of DNA act as molecular” switches “to activate the therapeutic gene into target cells, leading strong and specific gene expression to rod and cone photocopies even in the middle to the end of the disease,” explains Sudharsan.
“Most used candidates have only been tested on healthy animal models and their performance is often reduced when the retina degenerates,” Sudharsan continues. “On the contrary,” he says, “the newly acquired candidates were selected based on their ability to activate gene activity in retina who had already lost more than half of their photobes who gave them more relevant to the stages of the disease.” In head-to-head comparisons, new promoters exceeded the widely used GRK1 promoter in both expression and specialization.
This study deals with one of the biggest obstacles to IRD treatment: how to deliver effective gene therapy after much of the retina has already degenerated. We were particularly excited by the performance of GNGT2-Candidates who have shown strong expression both on rods and cones, even in advanced stages of illness. And their small size under 850 base pairs makes them ideal for [adeno-associated virus] AAV packaging, as opposed to certain conventional cone motivation that are significantly larger. ”
Raghavi Sudharsan, Assistant Professor of Experimental Ophthalmology, Veterinary School of the University of Pennsylvania
The team also stressed that the high specialization of these promotional promotions could help reduce the impact of off-target and reduce potential immunocommal-semantic estimates of safety and long-term efficiency.
The researchers used a combination of transcriptional analysis, in Silico and in vivo sorting on large animal models to identify a series of new, short promotions that remain active in degenerative photocytes. They include candidates coming from GNGT2; Impg2; PDE6H The genes, which showed strong, cellular specific expression when delivered through AAVs to the retina dogs mimic human IRDs.
“These findings emphasize the importance of promotion tests in clinical related models and appropriate stages of illness, which unfortunately cannot be established in cellular crops or organoids of the retina,” says senior writer William A. Beltran, who directs the Divine Liturgy. “They lay the foundations for a new generation of gene therapies that are more powerful, accurate and responding to the real clinical needs of patients with hereditary degenerations of the retina, either individuals or animals.”
A temporary patent for promotion technology has been deposited by the University of Pennsylvania.
William Beltran is Corinne R. and Henry Bower, gifted professor of ophthalmology and director of the Department of Experimental Retinal Therapies in the Department of Clinics and Advanced Medicine at the University of Pennsylvania Veterinary School.
Raghavi Sudharsan is Assistant Research Professor of Experimental Ophthalmology in the Department of Clinics & Advanced Medicine in Penn Vet.
Other authors are Gustavo D. Aguirre, Aditi Ahuja, Natalia Dolgova, Valerie L. Dufor, Jennifer Kwok, Leonardo Murgiano, Yu Sato and Svetlana Savina of Penn Vet and Leah C. Byrne and Morganovitz of the University of Pittsburgh of Medicine.
This project was supported by NIH GRANTS RO1-EY006855, RO1-EY017549, RO1-EY033049 and P30-EY001583, the Foundation for the Pennsylvania (Beltran).
Source:
Magazine report:
Sudharsan, R., et al. (2025). New promotional promotional promoter for gene therapy in the middle to the duration of retinal degeneration. Molecular therapy. Doi.org/10.1016/j.YMTHE.2025.05.020.
